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Summary
Muscle-eye-brain disease (MEB) is an autosomal reces-
sive disease of unknown etiology characterized by severe
mental retardation, ocular abnormalities, congenital
muscular dystrophy, and a polymicrogyria-pachygyria–
type neuronal migration disorder of the brain. A similar
combination of muscle and brain involvement is also
seen in Walker-Warburg syndrome (WWS) and Fuku-
yama congenital muscular dystrophy (FCMD). Whereas
the gene underlying FCMD has been mapped and
cloned, the genetic location of the WWS gene is still
unknown. Here we report the assignment of the MEB
gene to chromosome 1p32-p34 by linkage analysis and
homozygosity mapping in eight families with 12 affected
individuals. After a genomewide search for linkage in
four affected sib pairs had pinpointed the assignment to
1p, the MEB locus was more precisely assigned to a 9-
cM interval flanked by markers D1S200 proximally and
D1S211 distally. Multipoint linkage analysis gave a
maximum LOD score of 6.17 at locus D1S2677. These
findings provide a starting point for the positional clon-
ing of the disease gene, which may play an important
role in muscle function and brain development. It also
provides an opportunity to test other congenital mus-
cular dystrophy phenotypes, in particular WWS, for
linkage to the same locus.
Introduction
Several genetic diseases occur at substantially higher fre-
quencies in Finland than in the rest of the world because
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of the particular features of the Finnish population,
which has expanded, in isolation, from a small number
of founders ∼100 generations ago (de la Chapelle 1993).
Muscle-eye-brain disease (MEB; MIM 253280) is a typ-
ical example of these disorders, which constitute the so-
called “Finnish disease heritage.” MEB is inherited in
an autosomal recessive manner and was first described
in Finnish patients by Santavuori et al. (1977). World-
wide, ∼30 patients with MEB have been reported, the
majority from Finland, where the incidence of this dis-
order is estimated to be !1:50,000. Outside Finland,∼10
sporadic cases bearing a close resemblance to MEB have
been described (Korinthenberg et al. 1984; Echenne et
al. 1986; Mielke et al. 1986; Federico et al. 1988; Leyten
et al. 1992; Topaloglu et al. 1995; van der Knaap et al.
1997).
MEB patients present with congenital hypotonia,
mental retardation, and visual failure (Raitta et al. 1978;
Santavuori et al. 1989; Pihko et al. 1995). The occur-
rence of severe progressive myopia from infancy is typ-
ical, whereas retinal degeneration with pale retina and
low or isoelectric electroretinogram, as well as cataracts,
develop with age. In addition, optic atrophy and delayed
and giant (150 mV) flash visual evoked potentials (VEP)
are typical in MEB. This VEP finding, present in 10 of
11 Finnish patients studied, strongly supports the di-
agnosis of MEB (Santavuori et al. 1998). The serum
creatine kinase (CK) levels are elevated, findings from
electromyography (EMG) show myopathy, and muscle
biopsy findings are compatible with dystrophy. Magnetic
resonance imaging (MRI) studies of the CNS reveal a
uniform structural pattern characterized by a nodular
cortical surface combined with midline defects and a flat
brainstem (Valanne et al. 1994). The cerebral and cer-
ebellar cortices are totally disorganized, without hori-
zontal lamination (Haltia et al. 1997).
Clinically, MEB resembles Fukuyama congenital mus-
cular dystrophy (FCMD; MIM 253800) (Fukuyama et
al. 1981) and Walker-Warburg syndrome (WWS; MIM
236670) (Dobyns et al. 1989), with confusing overlap
in individual patients. All three conditions share the un-
usual combination of congenital muscular dystrophy
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(CMD) and congenital brain malformations. In addition,
ocular abnormalities are typical in WWS and in MEB.
Although the clinical features of FCMD are well char-
acterized, the delineation of WWS and MEB has re-
mained controversial (Dubowitz 1997). It has been sug-
gested that MEB and WWS should be considered the
same clinical entity (Dobyns et al. 1989, 1990). How-
ever, two of us (P.S. and H.P.), after evaluation of 19
Finnish patients, argued for the distinctness of MEB
(Santavuori et al. 1990). The clinical presentation of
MEB seems to be uniform in Finland, with the exception
of two patients (Valanne et al. 1994). The final resolu-
tion of the controversies between the different patient
groups will depend on the mapping and characterization
of the underlying gene defects. In that regard, the gene
for FCMD has been localized to chromosome 9q31-q33
(Toda et al. 1993) and recently identified (Kobayashi et
al. 1998). A linkage study of seven Finnish MEB families
with 12 affected individuals showed that the MEB phe-
notype was not linked to the FCMD locus (Ranta et al.
1995). The gene for WWS has not yet been mapped.
Here we report the localization of the MEB gene to
chromosome 1p32-p34. We performed a genomewide
search for linkage, using a set of microsatellite markers
with an average spacing of 10 cM, initially in four Fin-
nish sib-pairs and their parents. The MEB gene was fur-
ther localized to a 9-cM interval by means of a com-
bination of linkage analysis and homozygosity mapping
in four additional pedigrees.
Subjects and Methods
Subjects and Samples
Seven Finnish (F1–F7) families and one Turkish (T1)
family, with a total of 12 affected individuals and 27
unaffected relatives, were studied. Four of the families
had two affected children, whereas the rest had only one
affected child. Two of the pedigrees, F7 and T1, were
consanguineous. Genealogic studies were performed on
family F7, which was traced back six generations in
search of common ancestors. Several consanguinity
loops were found at different levels. The pedigree struc-
tures are shown infigure 1.
The MEB diagnosis in the Finnish patients was based
on the presence of the following findings: severe mental
retardation, ocular changes including myopia 16 di-
opters, hypotonia and weakness, myopathic/dystrophic
changes in muscle biopsy specimens, myopathic EMG
findings and/or elevated serum CK values, as well as the
presence of cobblestone cortex, midline defects, abnor-
mally thin brainstem, and cerebellar hypoplasia, with
absent inferior vermis in MRI studies (fig. 2). The symp-
toms were present from birth or the first months of life.
Detailed clinical data from the MEB patient in family
T1 are given in Topaloglu et al. (1995), where the pro-
positus is referred to as “case 1.” The main clinical fea-
tures of the Finnish and Turkish patients are summarized
in table 1.
Genomic DNA was isolated by standard methods
from venous blood or fibroblast or lymphoblast cell lines
from all consenting individuals. All samples from Finn-
ish families were drawn in accordance with the Helsinki
declaration.
Genotyping
For the genomewide search, we analyzed DNA sam-
ples by PCR amplification using a panel of 350 highly
polymorphic microsatellite markers with an average
spacing of 10 cM, mainly from the Ge´ne´thon collection
(Dib et al. 1996), as described elsewhere (Avela et al.
1997). In the initial screening, four multiplex nuclear
families were scored for the presence or absence of re-
combinations by familywise comparison of the alleles of
affected individuals. The parents were also genotyped to
assess the informativity of the markers. If both affected
sibs in a family had the same genotype, the family was
scored with a plus sign; if not, the family was marked
with a minus sign. Markers giving four plus signs were
selected for further study.
For the refinement of the candidate area on chro-
mosome 1p, we used the tetranucleotide repeat markers
D1S552, D1S2134, D1S1669, and D1S1665 from the
Cooperative Human Linkage Center collection (Murray
et al. 1994), as well as the dinucleotide repeat markers
D1S234, D1S513, D1S255, D1S2743, D1S193,
D1S211, D1S2677, D1S2824, D1S2748, D1S427,
D1S197, D1S200, D1S220, D1S209, D1S438, and
D1S198 from the Ge´ne´thon collection (Dib et al. 1996).
Primers were purchased from the MapPairs set (Research
Genetics) or were synthesized with sequence data from
the CEPH public database. In all cases the forward
primer was modified at the 5′ end with a FAM, TET, or
HEX fluorescent label. The order and distances (in cen-
timorgans) of the markers used in the linkage analysis
are depicted in figure 3. The most likely location for
markers D1S552, D1S2134, D1S1669, and D1S1665
was computed by the CMAP program of the LINKAGE
package (Lathrop et al. 1984) and was based on data
from all the available CEPH reference families. Each of
these four tetranucleotide repeat markers was run over
a fixed set of markers from the Ge´ne´thon map (Dib et
al. 1996). The multipoint LOD scores supporting the
locations of markers D1S552, D1S2134, D1S1669, and
D1S1665, given in figure 3, were 36.10, 26.91, 32.65,
and 39.09, respectively.
The PCR reactions were performed under the follow-
ing conditions: 50 ng genomic DNA, 1′# Perkin-Elmer
PCR buffer, 130 mM dNTPs, 5 pmol of both the forward
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Figure 1 A (opposite), Pedigrees of the Finnish MEB families F1–F6, showing haplotypes for 12 polymorphic markers on 1p. Affected
individuals are denoted by blackened symbols, deceased family members are indicated by diagonal slashes, and consanguineous matings are
marked by double lines. The haplotypes segregating with the disease phenotype are shown by black bars situated between the marker alleles.
Families F1, F2, F3, and F5 were used in the first stage of the genomewide screening. Individuals II-3 and II-4 from family F4 did not fulfill
the diagnostic criteria for MEB and were thus excluded from the initial linkage studies. The haplotype analysis on 1p excluded linkage to the
MEB locus in these two individuals (see the Results section). B (above), Pedigrees of the consanguineous MEB families F7 (Finnish) and T1
(Turkish). Affected individuals are denoted by blackened symbols. Haplotypes for 20 markers surrounding the MEB gene on 1p are shown.
The regions of homozygosity are indicated by black bars. tel  telomere; cen  centromere.
and reverse primer, and 0.75 U AmpliTaq Gold poly-
merase (Perkin-Elmer) in a final volume of 15 ml. The
amplification conditions were 94C for 10 min for 1
cycle; 94C for 30 s, 55C for 1 min 15 s, and 72C for
1 min, for 30 cycles (FAM and TET markers) or 35
cycles (HEX markers); and 72C for 10 min. Amplified
products were separated by electrophoresis on a 4.25%
polyacrylamide-6 M urea gel by a 377 DNA sequencer
apparatus (Applied Biosystems), and the results were
processed by GENESCAN version 2.0.2 and GENO-
TYPER version 1.1 software.
Linkage Analysis
We used simulation programs SLINK and MSIM, ver-
sion 2.51 (Weeks et al. 1990), to compute the maximum
expected pairwise LOD scores in our panel of MEB fam-
ilies, assuming a marker heterozygosity value of 0.7 over
100 replicates. The initial panel of four families was
estimated to give a maximum two-point LOD score
(Zmax) of 2.41 at a recombination fraction (v) of 0.00
from the disease gene and a Zmax of 1.72 at .v  0.10
When all the family material available was considered,
the expected Zmax was 4.15 at and 2.83 atv  0.00
.v  0.10
Pairwise LOD scores were calculated by the MLINK
program of the LINKAGE package, version 5.2 (Lathrop
et al. 1984). An autosomal recessive model of inheritance
with complete penetrance and a population frequency
of 0.004 for the disease allele was assumed. The allele
frequencies of the polymorphic markers were considered
to be equal. Inbreeding loops were broken by the MAK-
EPED program, by counting twice an individual who
had both parents and children included in the pedigree.
We used the GENEHUNTER program (Kruglyak et
al. 1996) to calculate multipoint LOD scores for MEB
against a fixed map of seven marker loci, assuming equi-
librium between the marker and test loci. The param-
eters in the multipoint analysis were the same as those
described for the two-point analysis. The 95% confi-
dence limits for the maximum recombination fraction
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Figure 2 MRI features of the brain of an MEB patient. Sagittal
view showing an enlarged lateral ventricle, thin corpus callosum, ab-
sent pons, abnormal tectum, and cerebellar atrophy with absent ver-
mis. The patient also has a pachygyria-type cortical migration defect.
Table 1
Clinical Features of the MEB Patients Included in this Study
Family
and
Patient
Present
Age
(years)
MRI
Findingsa
VEPb
(mV)
Myopia
(D)
Serum
CKc
F1:
II-1 17d Typical 150 17 2.2–71
II-2 15 Typical Deformede 26 1.8–5.4
F2:
II-1 27 Typical 150 27 2.1–8.8
II-2 22 Typical 150 10 3.1–5.9
F3:
II-1 35d Typical 150 NAf 1.2–6.1
II-2 41 Typical 150 10 0.2–2.9
F4:
III-2 22d Typical 150 9 2.3–40.2
F5:
III-2 14 Typical 150 25 5.0–5.4
III-3 9 Typical 30 18 3.2–3.8
F6:
II-2 20 Typical 150 15 1.0–28
F7:
III-1 21 Typical 150 25 2.0–18.2
T1:
II-1 11 Typical NAg 13 25–38
a Typical  flat brainstem, midline defects, nodular cortical surface,
and cerebellar hypoplasia with absent inferior vermis.
b Normal 10–15 mV (Santavuori et al. 1998).
c Times the upper limit of normal.
d Age at death.
e Extreme hydrocephalus.
f Refraction could not be measured because of cataract at the age
of 34 years.
g Not available.
(vmax) at the Zmax both in the multipoint and in the two-
point analyses were calculated by the 1-LOD-down
method (Ott 1992).
Linkage Disequilibrium and Haplotype Analysis
We evaluated the presence of linkage disequilibrium
between the disease and marker loci, using the program
DISLAMB version 2.1, which applies a likelihood-ratio
test for linkage disequilibrium with only 1 df, irrespec-
tive of the number of alleles at a given marker (Terwil-
liger 1995). Sixty chromosomes from healthy Finnish
individuals were genotyped for all the markers and used
as controls in the calculations.
Haplotypes for 12 microsatellite markers over the
MEB region were constructed in families F1 to F6 (fig.
1A). We performed homozygosity mapping (Lander and
Botstein 1987) in the two consanguineous families (F7
and T1,fig. 1B), using extended haplotypes for 20 mark-
ers. The haplotypes were constructed manually by as-
suming the minimum number of recombinations, and
the phase was determined by genotyping all the available
family members.
Results
Initial Assignment of the MEB Gene
The screening to locate the MEB gene was performed
in two stages. In the first stage, a genomewide scan in
four Finnish families (F1, F2, F3, and F5;fig. 1A) was
performed to identify genomic regions showing allele
sharing within sibships (see the Subjects and Methods
section for details). This method yielded only four loci
on chromosomes 1p, 5p, 8q, and 12q that showed allele
sharing in all four families. In the second stage of the
screening, we studied the four candidate regions further,
using all available families (fig. 1). The locations on chro-
mosome 5p, 8q, and 12q were excluded (data not
shown), whereas the marker D1S197 on 1p continued
to provide evidence for linkage, with atZ  2.81max
from the disease gene.v  0.00
Refinement of the Critical Region by Linkage Analysis
in an Extended Panel of Families
The analysis of additional markers closely linked to
D1S197 and additional families confirmed the location
of the MEB gene on 1p. The results of the two-point
linkage calculations between MEB and 12 markers on
chromosome 1p are shown in table 2, and the linkage
map for these markers is depicted in figure 3. Four mark-
ers (D1S2134, D1S2677, D1S2824, and D1S2748)
provided statistically significant pairwise LOD scores
( ) without observed recombination events.Z 1 3.0max
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Figure 3 Ideogram of chromosome 1, showing the location and
the relative order of and distances (in centimorgans) between the mark-
ers analyzed in this study. The MEB locus interval as defined by re-
combination events in affected individuals is indicated by a white bar.
Blackened bars indicate regions of homozygosity in the affected sibs
in the consanguineous families F7 and T1. Taken together, the data
suggest that the MEB gene lies in a 9-cM interval between markers
D1S211 and D1S200.
The highest LOD score was obtained with D1S2677
( at ). The MEB locus region wasZ  4.46 v  0.00max
bordered by obligatory recombinations, observed with
marker D1S193 at the telomeric side (family F6) and
D1S200 toward the centromere (family F2). These flank-
ing markers are separated by 10.5 cM and are physically
located on chromosome 1p32-p34 (Hellsten et al. 1995;
Collins et al. 1996; Speleman et al. 1996). Multipoint
linkage analysis, calculated for a subset of seven mark-
ers, resulted in a maximum LOD score of 6.17 at
D1S2677, with a 1 LOD unit support interval of 2.07
cM distal and 5.5 cM proximal to it.
In family F4 (fig. 1A), individuals II-3 and II-4, who
are sibs from a consanguineous marriage, presented with
a milder “MEB-like” phenotype. They are still alive at
67 and 62 years and show mild mental retardation, cat-
aracts, and muscular dystrophy. Moreover, findings from
the MRI scans are normal and very different from the
uniform malformation pattern present in the “typical”
MEB patients, including individual III-2 from the same
family (Santavuori et al. 1989; Valanne et al. 1994).
Because no homozygosity or cosegregation with the dis-
ease was seen for the marker alleles in the MEB region
in II-3 and II-4, and because they did not share a hap-
lotype with III-2, the 1p32-p34 MEB locus was excluded
as the one responsible for this phenotype.
Homozygosity Mapping in Two Inbred Pedigrees
To further refine the location of the MEB gene, we
attempted homozygosity mapping. Extended haplotypes
were constructed in two consanguineous kindreds (F7
and T1) with 20 microsatellite markers. The results are
shown infigure 1B, and the distances between the mark-
ers are shown in figure 3. As expected on the basis of
homozygosity by descent, regions of allele homozygosity
were observed in the MEB locus region in the two af-
fected individuals. The affected sib from family T1 is
homozygous for the alleles of all informative markers
proximal to D1S255 and distal to D1S1669, spanning
a region of ∼26 cM on 1p. The maximum region of
homozygosity in individual III-1 from family F7 spans
14 cM from D1S211 to D1S220. These data further
restrict the telomeric boundary of the MEB critical re-
gion to marker D1S211. The combined homozygosity
and recombinational mapping data give the MEB gene
a most likely location in an ∼9-cM interval between
D1S211 and D1S200 (fig. 3).
Linkage Disequilibrium and Haplotype Analysis
All the markers within the MEB critical region span-
ning D1S211 and D1S200 were analyzed for linkage
disequilibrium by comparing our set of 13 apparently
unrelated Finnish disease chromosomes with a panel of
60 Finnish healthy chromosomes. The results were not
significant in any case (data not shown). No major com-
mon haplotype was observed in the Finnish MEB
chromosomes.
Discussion
CMDs comprise a heterogeneous group of inherited
neuromuscular disorders characterized by early onset of
hypotonia and weakness, joint contractures, muscular
dystrophy, and a slowly progressive course. Several
forms of CMD show brain involvement in addition to
the muscle features. The LAMA2 gene, encoding the
laminin a2 chain or merosin, located on chromosome
6q22, has been identified as the cause of one of these
disorders (Helbling-Leclerc et al. 1995). Mutations in
this gene are responsible for ∼50% of CMD cases in the
white population (Voit 1998). CMD patients with a mer-
osin deficiency form a clinically homogeneous group
characterized by cerebral involvement, in the form of
white-matter changes without mental retardation. By
contrast, merosin-positive CMD is clinically more var-
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Table 2
Two-Point LOD Scores for Linkage Between the MEB Locus and 12 Chromosome 1p Markers
LOCUS
LOD SCORE AT v 
Zmax vmax
95%
CONFIDENCE
INTERVAL a.00 .01 .05 .10 .20 .30 .40
D1S552  4.17 1.62 .74 .16 .01 .01 .01 .390 )
D1S193  1.43 1.89 1.77 1.19 .61 .20 1.89 .056 )
D1S211 2.83 2.75 2.39 1.97 1.20 .59 .18 2.83 .000 )
D1S2134 3.91 3.78 3.26 2.65 1.58 .75 .23 3.91 .000 .000 ! v ! .079
D1S2677 4.46 4.31 3.72 3.01 1.78 .85 .26 4.46 .000 .000 ! v ! .068
D1S2824 4.31 4.16 3.59 2.92 1.74 .84 .25 4.31 .000 .000 ! v ! .071
D1S2748 3.12 3.05 2.70 2.22 1.33 .65 .21 3.12 .000 .000 ! v ! .110
D1S427 2.34 2.26 1.94 1.56 .91 .42 .11 2.34 .000 )
D1S197 2.81 2.71 2.29 1.81 1.03 .49 .15 2.81 .000 )
D1S200  1.24 1.53 1.35 .85 .43 .15 1.53 .043 )
D1S1669  .70 .40 .69 .64 .37 .11 .73 .133 )
D1S1665  2.92 1.14 .54 .15 .04 .01 .00 .500 )
a Confidence intervals for v were calculated for the statistically significant Zmax values by means of the
1-LOD-down method (Ott 1992).
iable, which suggests that it may comprise a genetically
heterogeneous group of disorders. Two genes responsible
for merosin-positive CMD have been mapped so far: the
Fukuyama-type CMD (or FCMD), on 9q31-q33 (Toda
et al. 1993), and CMD with early rigidity of the spine
(or CMD-RSS), on 1p35-p36 (Moghadaszadeh et al.
1998). The FCMD gene was identified recently (Kobay-
ashi et al. 1998). It encodes a novel protein, termed
“fukutin,” that is secreted outside the cell and thus could
have a role as a constituent of the extracellular matrix
complex of muscle membranes (Kobayashi et al. 1998).
Here we report the localization of a third gene for a
merosin-positive CMD, MEB, to chromosome 1p32-
p34. The data presented confirm the recessive mode of
inheritance suggested by previous pedigree studies (San-
tavuori et al. 1989). Interestingly, both the CMD-RSS
and the MEB loci map to the distal short arm of chro-
mosome 1. However, since the regions of homozygosity
found in the three consanguineous CMD-RSS families
reported by Moghadaszadeh et al. (1998) do not overlap
with the MEB critical region reported in the present ar-
ticle, the possibility that these two disorders are allelic
can be excluded.
Three conditions—FCMD, WWS, and MEB—share
the combination of CMD and brain malformations. The
nosological classification of these disorders has been
controversial (Dubowitz 1997). Clinically, the distin-
guishing factor between MEB, WWS, and FCMD is the
extent of ocular involvement. Severe malformations, in-
cluding malformation of the anterior chamber and per-
sistent primary vitreous, are typical of WWS. Simple
myopia without structural changes occurs in some
FCMD patients. The characteristic ocular malformation
of MEB is that of progressive myopia and retinal de-
generation associated with giant visual evoked poten-
tials. The typical brain malformation in WWS is called
“lissencephaly II,” or a brain with smooth surface. The
nodular cortical migration defect (Takada et al. 1984;
Haltia et al. 1997) is similar in MEB and FCMD, but
the brain stem, which is characteristically flat in MEB,
is normal in FCMD. The clinical course of WWS is very
severe, and many patients die in early infancy, which is
not usually the case in MEB. The clinical course of
FCMD is similar to that of MEB. Although the clinical
data suggest that MEB is an independent nosological
entity, only the resolution of the molecular genetic back-
ground of these three disorders will eventually clarify
the existing controversy. In this regard, the FCMD locus
was previously excluded as the cause for MEB in Finnish
families (Ranta et al. 1995). The genetic localization of
the MEB gene now provides an opportunity to test the
hypothesis of WWS and MEB being allelic disorders.
The genes encoding a number of muscle basement
membrane proteins such as laminins and integrins may
be considered good candidates for MEB, for several rea-
sons. First, some of them are mutated in other muscle
disorders: laminin a2 in merosin-negative CMD (Hel-
bling-Leclerc et al. 1995) and integrin a7 in a mild form
of congenital myopathy (Hayashi et al. 1998). Second,
these proteins have been shown to interact with proteins
which, when deficient, cause muscular dystrophy
(Campbell 1995). Finally, several laminins are expressed
both in muscle and in CNS, and they have been asso-
ciated with several neuronal processes, including stim-
ulation of the migration of neuronal cells (Calof and
Lander 1991; Engvall et al. 1992). Laminins are a family
of extracellular matrix proteins that are composed of
three different but homologous chains named a, b, and
g (Hagg et al. 1997), and integrins are a family of het-
erodimeric adhesion molecules composed of an a and a
b subunit (Hynes 1992). Members of both families are
involved in the formation of a link between the extra-
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cellular matrix and the subsarcolemmal cytoskeleton,
providing functional integrity to muscle cells.
In MEB, immunohistochemical studies have revealed
a consistently weak staining for laminin a2 in muscle
(Haltia et al. 1997). This feature, as well as a weak
staining for other laminin subunits, is also seen in FCMD
(Hayashi et al. 1993). Given that the location of the
MEB gene on chromosome 1p32-p34 excludes all the
already mapped laminin and integrin genes as the ones
underlying the disease, the observed changes in the
membrane protein composition in MEB patients are
most probably secondary. It is thus tempting to speculate
that a primary deficiency of another interacting base-
ment membrane protein may cause the destabilization
of the membrane complex. Similar “combined deficien-
cies” have been reported in other muscular disorders
such as the limb-girdle-type muscular dystrophy (Bo¨n-
nemann et al. 1995) and Duchenne muscular dystrophy
(Campbell 1995).
On-line searches for genes mapped to 1p32-p34 in the
Genome Database resulted in a listing of 1100 genes.
At least three of them—the collagen VIII a-2 polypeptide
gene (COL8A2), the vascular cell adhesion molecule-1
gene (VCAM1), and the protein tyrosine phosphatase,
receptor type, f polypeptide gene (PTPRF)—are known
to encode basement membrane proteins and therefore
constitute functional candidates for MEB. Moreover, the
Human Gene Map at the National Center for Biotech-
nology Information lists 129 expressed sequence tags
situated within the MEB critical interval between mark-
ers D1S211 and D1S200 (Schuler et al. 1996). Thirteen
of these are derived from muscle, brain, and eye cDNA
libraries, and they may be considered as potential can-
didates for MEB. There are no known mouse mutations
specific for MEB, although the syntenic region on mouse
chromosome 4 contains the neuromuscular phenotype
mea (meander tail), characterized by ataxia, structural
cerebellar abnormalities, muscle weakness, and myopa-
thy (Dysmorphic Human-Mouse Homology Database).
Our current aim is to refine the localization of the
MEB gene by analyzing additional markers for linkage
disequilibrium in an extended panel of Finnish families,
ultimately to facilitate the positional cloning of the dis-
ease gene. Interestingly, no significant linkage disequi-
librium was detected for any of the markers we studied.
This may suggest a relatively old origin of the putative
founding mutation within the Finnish population. The
existence of several different mutations is a less likely
explanation. The extension of the panel of polymorphic
markers that will be analyzed in the critical region will
help to elucidate this point.
As MEB is both a CMD and a neuronal migration
disorder, the eventual identification and characterization
of the primary defect may help us to better understand
the pathophysiology of muscular dystrophies and may
provide new insights into normal and abnormal devel-
opment of the brain.
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